|Mr. Jeffrey R. Baxter F.C.M.A., FCMA||Pres, CEO & Director||736.13k||N/A||1961|
|Dr. David Evander Anderson||Chief Scientific Officer||452.7k||N/A||1970|
|Dr. Francisco Diaz-Mitoma FRCPC, M.D., Ph.D.||Chief Medical Officer||488.2k||N/A||1955|
|Mr. Christopher McNulty||CFO, Head of Bus. Devel. & Director||N/A||N/A||1977|
|Nicole Anderson||Director of Corp. Communications & Investor Relations||N/A||N/A||N/A|
|Ms. Athena Kartsaklis||Sr. VP of Fin., Chief Compliance Officer & Principal Financial Officer||N/A||N/A||1965|
|Ms. Nell Beattie||Chief Bus. Officer||N/A||N/A||1988|
|Mr. Avi Mazaltov||Global Head of Manufacturing & GM of SciVac||N/A||N/A||1962|
|Mr. Misha Nossov||Sr. VP of Market Access & Commercial||N/A||N/A||N/A|
|Mr. T. Adam Buckley||Sr. VP of Bus. Devel.||N/A||N/A||1976|
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. The company primarily serves physicians and pharmacists through direct sales. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition For Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.
VBI Vaccines Inc.’s ISS Governance QualityScore as of April 1, 2021 is 8. The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 4; Compensation: 10.